Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1983 Sep;58(9):703–708. doi: 10.1136/adc.58.9.703

Inhibitor of prostacyclin production in sporadic haemolytic uraemic syndrome.

M Levin, K B Elkon, T J Nokes, A M Buckle, M J Dillon, R M Hardisty, T M Barratt
PMCID: PMC1628234  PMID: 6354101

Abstract

Prostacyclin (PGI2) production was diminished when rat aortic rings were incubated with plasma from 5 of 6 patients with the sporadic form of haemolytic uraemic syndrome but was normal in the presence of plasma from 7 patients with the epidemic form of haemolytic uraemic syndrome or from patients with other renal diseases. The reduced PGI2 production was caused by an unstable inhibitor, extractable into polar lipid solvents, in sporadic haemolytic uraemic plasma. These results suggest that there may be at least 2 different pathogenetic mechanisms in epidemic and sporadic haemolytic uraemic syndrome and that the reduced PGI2 production observed in the sporadic type is due to an inhibitor of PGI2 production rather than a deficiency of stimulating factors.

Full text

PDF
703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Byrnes J. J., Khurana M. Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977 Dec 22;297(25):1386–1389. doi: 10.1056/NEJM197712222972507. [DOI] [PubMed] [Google Scholar]
  2. Chen Y. C., McLeod B., Hall E. R., Wu K. K. Accelerated prostacyclin degradation in the thrombotic thrombocytopenic purpura. Lancet. 1981 Aug 8;2(8241):267–269. doi: 10.1016/s0140-6736(81)90522-5. [DOI] [PubMed] [Google Scholar]
  3. Fong J. S., de Chadarevian J. P., Kaplan B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982 Aug;29(4):835–856. doi: 10.1016/s0031-3955(16)34216-x. [DOI] [PubMed] [Google Scholar]
  4. Gianantonio C. A., Vitacco M., Mendilaharzu F., Gallo G. E., Sojo E. T. The hemolytic-uremic syndrome. Nephron. 1973;11(2):174–192. doi: 10.1159/000180229. [DOI] [PubMed] [Google Scholar]
  5. Ham E. A., Egan R. W., Soderman D. D., Gale P. H., Kuehl F. A., Jr Peroxidase-dependent deactivation of prostacyclin synthetase. J Biol Chem. 1979 Apr 10;254(7):2191–2194. [PubMed] [Google Scholar]
  6. Kaplan B. S., Chesney R. W., Drummond K. N. Hemolytic uremic syndrome in families. N Engl J Med. 1975 May 22;292(21):1090–1093. doi: 10.1056/NEJM197505222922102. [DOI] [PubMed] [Google Scholar]
  7. Kobayashi Y., Okahata S., Tanabe K., Tanaka Y., Ueda K., Usui T. Erythrocyte superoxide dismutase activity in hemolytic uremic syndrome. Hiroshima J Med Sci. 1978 Sep;27(3):181–183. [PubMed] [Google Scholar]
  8. MacIntyre D. E., Pearson J. D., Gordon J. L. Localisation and stimulation of prostacyclin production in vascular cells. Nature. 1978 Feb 9;271(5645):549–551. doi: 10.1038/271549a0. [DOI] [PubMed] [Google Scholar]
  9. Machin S. J., Defreyn G., Chamone D. A., Vermylen J. Plasma 6-keto-PGF1 alpha levels after plasma exchange in thrombotic thrombocytopenic purpura. Lancet. 1980 Mar 22;1(8169):661–661. doi: 10.1016/s0140-6736(80)91160-5. [DOI] [PubMed] [Google Scholar]
  10. Moncada S., Higgs E. A., Vane J. R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18–20. doi: 10.1016/s0140-6736(77)91655-5. [DOI] [PubMed] [Google Scholar]
  11. O'Regan S., Chesney R. W., Kaplan B. S., Drummond K. N. Red cell membrane phospholipid abnormalities in the hemolytic uremic syndrome. Clin Nephrol. 1981 Jan;15(1):14–17. [PubMed] [Google Scholar]
  12. Pini M., Manotti C., Quintavalla R., Dettori A. G. Normal prostacyclin-like activity in thrombotic thrombocytopenic purpura. Thromb Haemost. 1981 Aug 28;46(2):571–571. [PubMed] [Google Scholar]
  13. Remuzzi G., Misiani R., Marchesi D., Livio M., Mecca G., de Gaetano G., Donati M. B. Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet. 1978 Oct 21;2(8095):871–872. doi: 10.1016/s0140-6736(78)91573-8. [DOI] [PubMed] [Google Scholar]
  14. Ridolfi R. L., Bell W. R. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore) 1981 Nov;60(6):413–428. [PubMed] [Google Scholar]
  15. Trompeter R. S., Schwartz R., Chantler C., Dillon M. J., Haycock G. B., Kay R., Barratt T. M. Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch Dis Child. 1983 Feb;58(2):101–105. doi: 10.1136/adc.58.2.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Webster J., Rees A. J., Lewis P. J., Hensby C. N. Prostacyclin deficiency in haemolytic-uraemic syndrome. Br Med J. 1980 Jul 26;281(6235):271–271. doi: 10.1136/bmj.281.6235.271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES